Skip to main content

Accelerate Diagnostics Value Stock - Dividend - Research Selection

Accelerate Diagnostics

ISIN: US00430H1023, WKN: A1KA68

Market price date: 21.09.2020
Market price: 11,24 USD




Accelerate Diagnostics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 29-03-2020
Cash flow
Net operating cash flow -64.794.000
Capital Expenditures -330.000
Free cash flow -65.124.000
Balance sheet
Total Equity -7.379.000
Liabilities & Shareholders equity 134.424.000
Income statement
Net income -84.305.000
Eps (diluted) -1,550
Diluted shares outstanding 56.203.300
Net sales/revenue 9.297.000

Fundamental ratios calculated on: 21-09-2020

Ratios
Key figures 21-09-2020
Cash flow
P/C -9,75
   
P/FC -9,70
Balance sheet
ROI-62,72
ROE-5,49
Income statement
P/E-7,25
Div. Yield0,00%
P/B-85,61
P/S67,95


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAXDX
Market Capitalization631.725.120,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-07-08,1231.000000/1230.000000; 1996-11-19,1.000000/4.000000
Internethttp://acceleratediagnostics.com


Description of the company

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://acceleratediagnostics.com